- Have any questions?
- +88-01714063309
- info@bdix.net
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (The Lancet)
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial (The Lancet)
July 20, 2020Encouraging results from phase 1/2 COVID-19 vaccine trials (The Lancet)
July 20, 2020The Lancet
20 July, 2020
Pedro M Folegatti, MSc, Katie J Ewer, PhD, Parvinder K Aley, PhD, Brian Angus, MD, Prof Stephan Becker, PhD, Sandra Belij-Rammerstorfer, PhD et al.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a zoonotic virus late in 2019 and is the causative agent of COVID-19. Exposure to SARS-CoV-2 can result in a range of clinical outcomes, varying from asymptomatic infection to severe acute respiratory distress and death. SARS-CoV-2 has spread globally and was declared a pandemic on March 11, 2020, by WHO. As of July 19, 2020, more than 14 million people globally have been infected with more than 597 000 deaths. The pandemic has placed substantial pressures on health systems delivering care for patients with COVID-19 and caused disruption of non-COVID-19 health-care provision, in addition to negative effects on the global economy. Further health consequences are anticipated.
Source: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931604-4